ArticleCancer gene therapy2009
Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers.
Article in Cancer gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Trial
- Review
- Lentiviral vector with a radiation-inducible promoter, carrying the ING4 gene, mediates radiosensitization controlled by radiotherapy in cervical cancer cells.Oncology letters · 2021Article
- GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status.OncoTargets and therapy · 2019Article
- Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.International journal of radiation oncology, biology, physics · 2017Review
- Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- CArG-driven GADD45α activated by resveratrol inhibits lung cancer cells.Genes & cancer · 2015Article
- A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Article
- New paradigms and future challenges in radiation oncology: an update of biological targets and technology.Science translational medicine · 2013Article
- Efficacy and safety of dendrimer nanoparticles with coexpression of tumor necrosis factor-α and herpes simplex virus thymidine kinase in gene radiotherapy of the human uveal melanoma OCM-1 cell line.International journal of nanomedicine · 2013Article
- Strategies to optimize radiotherapy based on biological responses of tumor and normal tissue.Experimental and therapeutic medicine · 2012Article
- Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.Medical oncology (Northwood, London, England) · 2012Article
- Chapter seven--Cancer treatment with gene therapy and radiation therapy.Advances in cancer research · 2012Review
- Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.Molecular cancer · 2011Article
- Article
- Combining radiation therapy with interstitial radiation-inducible TNF-α expression for locoregional cancer treatment.Cancer gene therapy · 2011Article
- Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma.Investigative ophthalmology & visual science · 2010Article
- Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- TNFerade, an innovative cancer immunotherapeutic.Indian journal of pharmacologyReview
- Harnessing the cell death pathway for targeted cancer treatment.American journal of cancer researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is a widely used treatment for localized malignancies that is often delivered in combination with cytotoxic chemotherapeutic agents. The concept that treatment of localized tumors can be improved with a radio- and chemo-inducible gene therapy strategy has been investigated in the laboratory and now translated to the clinic. The TNFerade (Ad.Egr-TNF11D) adenoviral vector was engineered by inserting radio- and chemo-inducible elements from the Egr-1 promoter upstream to a cDNA encoding tumor necrosis factor-alpha (TNF-alpha). Transduction of tumor cells with TNFerade and then treatment with radiation or chemotherapy is associated with spatial and temporal control of TNF-alpha secretion and enhanced antitumor activity. TNFerade has been evaluated in trials for patients with sarcomas, melanomas and cancers of the pancreas, esophagus, rectum and head and neck. If the ongoing phase III trial for pancreatic cancer is successful, TNFerade will likely become the first gene therapy approved for cancer in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.